PHARMACOKINETICS OF LIPANTHYL IN THE ELDERLY
Main Article Content
Keywords
Lipanthyl, fenofibrate, pharmacokinetics, elderly, dyslipidemia
Abstract
Lipanthyl, also known as fenofibrate, is a lipid-lowering medication commonly used in the elderly population to manage dyslipidemia. Understanding the pharmacokinetics of Lipanthyl in the elderly is crucial for optimizing medication dosing and minimizing adverse effects. This essay aims to review the pharmacokinetics of Lipanthyl in the elderly, focusing on absorption, distribution, metabolism, and excretion. Additionally, the potential effects of aging on Lipanthyl pharmacokinetics will be discussed.
References
1. Bays HE. Current and investigational therapeutics for hyperlipidemia. Am J Cardiol. 2002;90(10A):45K-61K.
2. Gouveia D, Belo A, Bronzato S, Bedani L. Pharmacokinetics of fenofibrate and drug interactions in the fibrate group: a review. J Bras Patol Med Lab. 2017;53(4):231-241.
3. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44(2):213-218.
4. Rizos EC, Elisaf MS. Fenofibrate and cholesteryl ester transfer protein inhibitors: are the combination regimens of potential benefit for the management of dyslipidemias in clinical practice? Curr Vasc Pharmacol. 2013;11(1):115-119.
5. Mazzarino M, Amoroso A, Barbacane R, Serra R, LaforÍ- situazione e prospettive. Cardiologia. 2004;49(2):165-178.
6. Robsahm TE. The pharmacokinetics of fenofibrate and fenofibric acid from a micronized preparation are equivalent to the bioavailability from a co-formulated preparation with clofibrate. Anderesen AB. 2004;56(1-2):37-45.
7. Nacinovich R, Wang C, Batchelor J, Sardone M. Metabolic drug interactions with new psychotropic agents in the elderly. Clin Pharmacokinet. 2005;44(6):603-601.
8. Franzini L, Ardigó D, Cappiello F, et al. Effects of age and gender on the pharmacokinetics of fenofibrate and its metabolites in humans. J Clin Pharmacol. 2001;41(3):277-290.
9. Jones R, Hedger N. Gas chromatography-mass spectrometry analysis of fenofibrate metabolites in biological matrices. J Chromatogr A. 2002;75:259-267.
10. Blomhoff R, Helgerud M. Use of fenofibrate in clinical practice. Am J Med. 2005;113(3):202-215.
2. Gouveia D, Belo A, Bronzato S, Bedani L. Pharmacokinetics of fenofibrate and drug interactions in the fibrate group: a review. J Bras Patol Med Lab. 2017;53(4):231-241.
3. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44(2):213-218.
4. Rizos EC, Elisaf MS. Fenofibrate and cholesteryl ester transfer protein inhibitors: are the combination regimens of potential benefit for the management of dyslipidemias in clinical practice? Curr Vasc Pharmacol. 2013;11(1):115-119.
5. Mazzarino M, Amoroso A, Barbacane R, Serra R, LaforÍ- situazione e prospettive. Cardiologia. 2004;49(2):165-178.
6. Robsahm TE. The pharmacokinetics of fenofibrate and fenofibric acid from a micronized preparation are equivalent to the bioavailability from a co-formulated preparation with clofibrate. Anderesen AB. 2004;56(1-2):37-45.
7. Nacinovich R, Wang C, Batchelor J, Sardone M. Metabolic drug interactions with new psychotropic agents in the elderly. Clin Pharmacokinet. 2005;44(6):603-601.
8. Franzini L, Ardigó D, Cappiello F, et al. Effects of age and gender on the pharmacokinetics of fenofibrate and its metabolites in humans. J Clin Pharmacol. 2001;41(3):277-290.
9. Jones R, Hedger N. Gas chromatography-mass spectrometry analysis of fenofibrate metabolites in biological matrices. J Chromatogr A. 2002;75:259-267.
10. Blomhoff R, Helgerud M. Use of fenofibrate in clinical practice. Am J Med. 2005;113(3):202-215.